- The disease
- Bladder cancer is one of the most common cancers globally, and its management requires repeated monitoring because the disease frequently recurs after initial treatment. Urothelial carcinoma — the most common subtype — can range from low-grade, slow-growing tumours to high-grade lesions that carry a higher risk of progression to muscle-invasive disease. Standard surveillance relies heavily on cystoscopy, an invasive procedure in which a camera is passed into the bladder. Identifying which patients carry high-grade disease is a key clinical challenge, as this determines the intensity of follow-up and treatment.
- What the asset is trying to do
- Cxbladder Resolve is a urine-based laboratory-developed test (LDT) that analyses the expression levels of a defined panel of genes in cells shed into the urine. Rather than looking for a single protein marker, the test uses a gene expression signature to identify the presence of high-grade urothelial carcinoma. The LDT classification means it is offered as a clinical service through Pacific Edge's laboratory rather than as a kit sold to other labs, and it is commercially available in the United States.
- What the trial is measuring, and why it matters
- The active trials associated with Pacific Edge's Cxbladder platform are measuring the test's diagnostic performance across several settings: screening in asymptomatic populations (per ClinicalTrials.gov NCT05646485), triage of patients presenting with unexplained blood in the urine — known as haematuria — to reduce the number of cystoscopies performed (per ClinicalTrials.gov NCT06394869), risk stratification in US veterans with microscopic haematuria (per ClinicalTrials.gov NCT05889195), and longitudinal monitoring for tumour recurrence (per ClinicalTrials.gov NCT05080998). Diagnostic performance endpoints typically include sensitivity, specificity, and the rate at which the test correctly identifies or excludes disease, which together inform whether a test can safely reduce the need for invasive procedures.
- Efficacy benchmarks in this setting
- Approved comparators and standard-of-care tools set the performance benchmark in this setting. Cystoscopy, the current standard, is considered the reference procedure against which urine biomarker tests are assessed. The FDA-cleared UroVysion fluorescence in situ hybridisation (FISH) assay has reported sensitivities for high-grade bladder cancer detection in the range of approximately 69-80% in published studies, though reported figures vary by study design and patient population; readers should consult individual publications for specific figures with full methodological context. The completed STRATA trial (NCT03988309) was a Pacific Edge-sponsored study designed to evaluate Cxbladder performance in asymptomatic microhaematuria — results from that trial are not yet cited in the input data provided. Early-stage or real-world diagnostic figures from a single developer's studies are not statistically comparable to the peer-reviewed performance data of cleared or approved competitor tests, and no such comparison is drawn here.